Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae1 1Appropriate informed consent was obtained, and clinical research was conducted in accordance with guidelines for human experimentation as specified by the institutional review boards or independent committees of the participating institutions.

Gatifloxacin is an advanced-generation fluoroquinolone with demonstrated efficacy and safety as therapy for community-acquired pneumonia (CAP). As part of a phase IV postmarketing surveillance program (TeqCES), 136 outpatients with CAP whose sputum was culture-positive for Streptococcus pneumoniae were enrolled in an open-label trial of oral gatifloxacin 400 mg daily for 7 to 14 days. An antibiogram of isolates showed 100% susceptibility to …